Efficacy and Safety of Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment and Dementia with Evidence of Both Amyloid-Beta and Vascular Pathology (U01 - Clinical Trial Required)

This RFA will solicit applications for a pivotal phase 3 clinical trial to determine the efficacy of FDA approved monoclonal antibody therapy compared to placebo in diverse "mixed dementia" populations with a focus on vascular contributions.

Mixed dementia refers to dementia cases positive


for 1) Alzheimer biomarkers, such as amyloid positron emission tomography and/or low cerebrospinal fluid amyloid beta 42 combined with elevated phosphorylated tau; and 2) evidence of vascular contributions based on imaging (white matter disease and/or subclinical infarction).

Bayesian approaches with response adaptive randomization to examine specific subgroups are engouraged.

Successful applications will be well-powered to determine efficacy in diverse populations representative of the effect of the disease in the United States by sex, race/ethnicity, and geographic distribution.

Applications must include patient and community engagement cores that are incorporated into all stages of program development and at all levels of the organizational structure.
Related Programs

Extramural Research Programs in the Neurosciences and Neurological Disorders

Department of Health and Human Services


Aging Research

Department of Health and Human Services






Obtain Full Opportunity Text:
https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-013.html

Additional Information of Eligibility:
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U. S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.

Non-domestic (non-U.S.) components of U. S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Full Opportunity Web Address:
http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-013.html

Contact:


Agency Email Description:
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.

Agency Email:


Date Posted:
2023-10-19

Application Due Date:


Archive Date:
2024-03-27


Ashoka, a global platform for social innovation, introduced the Arab World Social Entrepreneurship Programme (ASEP) to support local social entrepreneurs in scaling up their operations in three key areas – healthcare, environment and women participation for inclusive growth.






More Federal Domestic Assistance Programs


Small Business Investment Companies | Good Neighbor Next Door Sales Program | Scientific Research Combating Weapons of Mass Destruction | Team Nutrition Grants | Adult Viral Hepatitis Prevention and Control |  Site Style by YAML | Grants.gov | Grants | Grants News | Sitemap | Privacy Policy


Edited by: Michael Saunders

© 2004-2024 Copyright Michael Saunders